These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11394661)

  • 1. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
    Cammà C; Giunta M; Andreone P; Craxì A
    J Hepatol; 2001 Apr; 34(4):593-602. PubMed ID: 11394661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.
    Yang YF; Zhao W; Zhong YD; Xia HM; Shen L; Zhang N
    J Viral Hepat; 2009 Apr; 16(4):265-71. PubMed ID: 19220736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection.
    Baffis V; Shrier I; Sherker AH; Szilagyi A
    Ann Intern Med; 1999 Nov; 131(9):696-701. PubMed ID: 10577333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis.
    Benvegnù L; Chemello L; Noventa F; Fattovich G; Pontisso P; Alberti A
    Cancer; 1998 Sep; 83(5):901-9. PubMed ID: 9731893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.
    Zhang CH; Xu GL; Jia WD; Li JS; Ma JL; Ge YS
    Int J Cancer; 2011 Sep; 129(5):1254-64. PubMed ID: 21710498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
    Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
    J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causes of and prevention strategies for hepatocellular carcinoma.
    Cabibbo G; Maida M; Genco C; Antonucci M; Cammà C
    Semin Oncol; 2012 Aug; 39(4):374-83. PubMed ID: 22846856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
    Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
    J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.
    Innes H; Barclay ST; Hayes PC; Fraser A; Dillon JF; Stanley A; Bathgate A; McDonald SA; Goldberg D; Valerio H; Fox R; Kennedy N; Bramley P; Hutchinson SJ
    J Hepatol; 2018 Apr; 68(4):646-654. PubMed ID: 29155019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C.
    Miyake Y; Iwasaki Y; Yamamoto K
    Int J Cancer; 2010 Aug; 127(4):989-96. PubMed ID: 19957327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.
    Velosa J; Serejo F; Marinho R; Nunes J; Glória H
    Dig Dis Sci; 2011 Jun; 56(6):1853-61. PubMed ID: 21374066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons.
    Craxì A; Cammà C
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S287-92. PubMed ID: 20547316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
    Masuzaki R; Yoshida H; Omata M
    Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.